Open access · CC-BY
via OpenAlex
SENOLYTIC COMBINATION OF DASATINIB AND QUERCETIN: A REVIEW OF PRECLINICAL AND CLINICAL STUDIES
I.I. Morozov, N. N. Molkanov, N. M Kiseleva
Медико-фармацевтический журнал «Пульс» · 2025
Abstract
Societal modernization is driving a steady rise in life expectancy alongside declining birth rates. This demographic transition places a significant burden on social institutions, particularly healthcare systems. Age-related diseases are the leading cause of mortality globally: over 80% of individuals over 65 live with at least one chronic condition, and half of this group suffers from multiple comorbidities. Developing therapeutics that target the fundamental mechanisms of aging is a promising strategy for improving treatment outcomes for age-related diseases and, ultimately, enhancing the quality of life in the elderly. This review aims to present findings from preclinical and clinical studies on the combination of dasatinib and quercetin. It is based on an analysis of literature, primarily international but also including domestic sources, indexed in PubMed and eLibrary databases and retrieved via Google Scholar over the past decade. Analysis of available data suggests that selectively clearing senescent cells (senolysis) is a promising therapeutic strategy for preventing and treating many chronic age-related diseases. However, further research is necessary to confirm the clinical potential of this drug combination, specifically its safety profile, pharmacokinetics, and pharmacodynamics. Additionally, there is an urgent need to identify relevant and reliable biomarkers to objectively assess the efficacy of senolytic therapies. Keywords: celluar senescence(definition); senolytics(definition); dasatinib; quercetin; SASP.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.26787/nydha-2686-6838-2026-28-1-49-58
- Canonical
- link ↗
- Fetched
- 2026-11-15 MST
Cite this
APA
Morozov, I., Molkanov, N.N., & Kiseleva, N.M. (2025). SENOLYTIC COMBINATION OF DASATINIB AND QUERCETIN: A REVIEW OF PRECLINICAL AND CLINICAL STUDIES. <em>Медико-фармацевтический журнал «Пульс»</em>. https://doi.org/10.26787/nydha-2686-6838-2026-28-1-49-58
Vancouver
Morozov I, Molkanov NN, Kiseleva NM. SENOLYTIC COMBINATION OF DASATINIB AND QUERCETIN: A REVIEW OF PRECLINICAL AND CLINICAL STUDIES. Медико-фармацевтический журнал «Пульс». 2025. doi:10.26787/nydha-2686-6838-2026-28-1-49-58.
BibTeX
@article{ii2025SENOLY,
title = {SENOLYTIC COMBINATION OF DASATINIB AND QUERCETIN: A REVIEW OF PRECLINICAL AND CLINICAL STUDIES},
author = {I.I. Morozov and N. N. Molkanov and N. M Kiseleva},
journal = {Медико-фармацевтический журнал «Пульс»},
year = {2025},
doi = {10.26787/nydha-2686-6838-2026-28-1-49-58},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Mechanisms of Ageing and Development 2024
Open access · CC-BY
Fisetin as a senotherapeutic agent: Evidence and perspectives for age-related diseases
Mechanisms of ageing and development 2024
Citation only
Fisetin as a senotherapeutic agent: Evidence and perspectives for age-related diseases.
Journal of Translational Medicine 2025
Open access · CC-BY
Unleashing endogenous regeneration by senolytics
Stem Cell Research & Therapy 2025
Open access · CC-BY
Advances in mesenchymal stem cell and exosome-based therapies for aging and age-related diseases
Journal of Agricultural and Food Chemistry 2021
Citation only
Prospective Selective Mechanism of Emerging Senolytic Agents Derived from Flavonoids
Scientific Bulletin of the Izmail State University of Humanities Section «Pedagogical sciences» 2026
Open access · OA